Longfellow Sells a Brand-New Lab Into a Cooling Market

The Signal:

• A merchant developer is exiting a newly delivered spec lab rather than holding through lease-up.
• The trade repositions basis in a submarket where lab demand has softened.
• New buyers will underwrite lab risk at the right price.

Longfellow sold the Hatch Life Sciences building at 43-10 23rd Street in Long Island City for about 86.9 million dollars, per New York City records. The asset spans about 208,000 square feet across seven floors, with prebuilt lab suites and modular research space, and the buyer entity is tied to Pearl Realty Management. The sale comes as U.S. lab leasing slows and spec supply outpaces near-term demand.

Longfellow built and delivered a purpose-built lab, then sold it into a market where tenants are slower to sign. The read is a repricing of spec life-science risk: developers who committed capital during the 2021 and 2022 lab boom are clearing inventory rather than carrying vacancy.

This is how an over-built niche resets, not through headline distress but through developers rotating out and value buyers rotating in at a lower number. The prebuilt and modular fit-out widens the tenant funnel where speed-to-occupancy is the leasing edge.

Implications: For developers, spec lab delivered into soft demand is a hold-or-sell decision, and Longfellow chose sell. For investors, life-science basis is resetting toward levels where the income risk is priced. For operators, prebuilt and modular space leases first when demand is thin.